SPONSOR
OriCell Therapeutics Co., Ltd.
Total Trials
2
Recruiting
2
Phases
Phase 1, Phase 1, Phase 2
Conditions studied: Neoplasms, Plasma CellNeoplasms by Histologic TypeNeoplasmsHemostatic DisordersVascular DiseasesCardiovascular DiseasesParaproteinemiasBlood Protein DisordersHematologic DiseasesHemorrhagic Disorders
Clinical Trials by OriCell Therapeutics Co., Ltd.
NCT06271252 Phase 1
Recruiting
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
Neoplasms, Plasma Cell
NCT06182696 Phase 1, Phase 2
Recruiting
OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
Relapsed and/or Refractory Multiple Myeloma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology